BioCentury | Feb 3, 2021
Finance

Abingworth leans into company creation with largest-ever fund at $465M

...strategics Eli Lilly & Co. (NYSE:LLY), PPD Inc. (NASDAQ:PPD...
BioCentury | Jan 23, 2021
Management Tracks

Yale’s Fuchs joins Genentech, Roche; plus Lineage’s Roberts jumps on Longboard as CFO and Avidity, Xalud, AVM, Novavax

...Xalu­­d Therapeutics Inc. hired Die­m Nguyen as CEO. Nguyen was EVP of biopharma at PPD Inc. (NASDAQ:PPD).AVM...
BioCentury | Jan 9, 2021
Finance

Targeted oncology is having a moment, again

...major depressive disorder (MDD) and post-partum depression (PPD...
BioCentury | Nov 27, 2020
Deals

With $1.5B Sage deal, Biogen bolsters Phase III pipeline ahead of aducanumab decision

...III SKYLARK trial, to treat postpartum depression (PPD).The...
...and the Phase III ROBIN study in PPD...
BioCentury | Nov 20, 2020
Finance

Nov. 19 Quick Takes: Olema’s IPO, plus venture rounds for Imago, Medable,  China deal for AUM-Newsoara and Qiming’s $1.2B fund

...series C round led by Sapphire Ventures, with participation from existing investors GSR Ventures, PPD Inc. (NASDAQ:PPD...
BioCentury | Sep 15, 2020
Deals

Buoyed by Phase III data, Marinus aims for first NDA in a rare seizure disorder

...indication. Both readouts led to sharp declines in Marinus’ share price (see “Marinus Plummets After PPD...
BioCentury | Aug 20, 2020
Finance

Science 37, Castor raise funds as decentralized trials gain traction

...in a series D1 round led by existing investors Lux Capital, Redmile Group and PPD Inc. (NASDAQ:PPD...
BioCentury | Jun 17, 2020
Finance

Royalty’s $1.7B IPO latest sign of a biopharma market on a roll

...$1.9 billion offering by contract researcher PPD Inc., which had a postmoney valuation of $9 billion (NASDAQ:PPD...
BioCentury | Jun 6, 2020
Finance

Daily Chart: NASDAQ’s dazzling debuts

...Inc. Lyra Therapeutics Inc. ORIC Pharmaceuticals Inc. Keros Therapeutics Inc. Zentalis Pharmaceuticals Inc. Imara Inc. Passage Bio Inc. Revolution Medicines Inc. Beam Therapeutics Inc. PPD Inc. Schroedinger...
BioCentury | May 5, 2020
Finance

May 4 Quick Takes: Following Lyra’s success, Ayala readies for NASDAQ IPO; plus Medable and Hyloris

...raised to more than $45 million. GSR Ventures led the round with participation from PPD Inc. (NASDAQ:PPD...
Items per page:
1 - 10 of 286
BioCentury | Feb 3, 2021
Finance

Abingworth leans into company creation with largest-ever fund at $465M

...strategics Eli Lilly & Co. (NYSE:LLY), PPD Inc. (NASDAQ:PPD...
BioCentury | Jan 23, 2021
Management Tracks

Yale’s Fuchs joins Genentech, Roche; plus Lineage’s Roberts jumps on Longboard as CFO and Avidity, Xalud, AVM, Novavax

...Xalu­­d Therapeutics Inc. hired Die­m Nguyen as CEO. Nguyen was EVP of biopharma at PPD Inc. (NASDAQ:PPD).AVM...
BioCentury | Jan 9, 2021
Finance

Targeted oncology is having a moment, again

...major depressive disorder (MDD) and post-partum depression (PPD...
BioCentury | Nov 27, 2020
Deals

With $1.5B Sage deal, Biogen bolsters Phase III pipeline ahead of aducanumab decision

...III SKYLARK trial, to treat postpartum depression (PPD).The...
...and the Phase III ROBIN study in PPD...
BioCentury | Nov 20, 2020
Finance

Nov. 19 Quick Takes: Olema’s IPO, plus venture rounds for Imago, Medable,  China deal for AUM-Newsoara and Qiming’s $1.2B fund

...series C round led by Sapphire Ventures, with participation from existing investors GSR Ventures, PPD Inc. (NASDAQ:PPD...
BioCentury | Sep 15, 2020
Deals

Buoyed by Phase III data, Marinus aims for first NDA in a rare seizure disorder

...indication. Both readouts led to sharp declines in Marinus’ share price (see “Marinus Plummets After PPD...
BioCentury | Aug 20, 2020
Finance

Science 37, Castor raise funds as decentralized trials gain traction

...in a series D1 round led by existing investors Lux Capital, Redmile Group and PPD Inc. (NASDAQ:PPD...
BioCentury | Jun 17, 2020
Finance

Royalty’s $1.7B IPO latest sign of a biopharma market on a roll

...$1.9 billion offering by contract researcher PPD Inc., which had a postmoney valuation of $9 billion (NASDAQ:PPD...
BioCentury | Jun 6, 2020
Finance

Daily Chart: NASDAQ’s dazzling debuts

...Inc. Lyra Therapeutics Inc. ORIC Pharmaceuticals Inc. Keros Therapeutics Inc. Zentalis Pharmaceuticals Inc. Imara Inc. Passage Bio Inc. Revolution Medicines Inc. Beam Therapeutics Inc. PPD Inc. Schroedinger...
BioCentury | May 5, 2020
Finance

May 4 Quick Takes: Following Lyra’s success, Ayala readies for NASDAQ IPO; plus Medable and Hyloris

...raised to more than $45 million. GSR Ventures led the round with participation from PPD Inc. (NASDAQ:PPD...
Items per page:
1 - 10 of 286